Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: Evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy

Cancer Research

Volumn 61, Issue 23, 2001, Pages 8422-8428

  Minotti, Giorgio ^a   Salvatorelli, Emanuela ^a   Menna, Pierantonio ^a   Ronchi, Raffaella ^b   Cairo, Gaetano ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 IMINODAUNORUBICIN; ACONITATE HYDRATASE; DAUNORUBICIN; DOXORUBICIN; DOXORUBICINOL; DRUG METABOLITE; FERRITIN; IRON REGULATORY FACTOR; IRON REGULATORY PROTEIN 1; IRON REGULATORY PROTEIN 2; IRON SULFUR PROTEIN; MESSENGER RNA; MITOXANTRONE; REACTIVE OXYGEN METABOLITE; REGULATOR PROTEIN; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

ALCOHOL METABOLISM; ANIMAL CELL; ARTICLE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CATALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG METABOLISM; DRUG PROTEIN BINDING; HEART MUSCLE CELL; HUMAN; IRON METABOLISM; IRON STORAGE; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN BINDING; RAT; REGULATORY MECHANISM; RNA BINDING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELLS, CULTURED; DOXORUBICIN; HEART; HEART DISEASES; IRON REGULATORY PROTEIN 1; IRON REGULATORY PROTEIN 2; IRON-REGULATORY PROTEINS; IRON-SULFUR PROTEINS; MYOCARDIUM; RATS; REACTIVE OXYGEN SPECIES; RNA-BINDING PROTEINS;

EID: 0035576817     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy
2. The role of iron in doxorubicin-induced cardiomyopathy
3. Role of iron in anthracycline cardiotoxicity: New tunes for an old song?
4. Regulating the fate of mRNA: The control of cellular iron metabolism
5. Aconitase, a two-faced protein: Enzyme and iron regulatory factor
6. Molecular control of vertebrate iron metabolism: Mrna based regulatory circuits operated by iron, nitric oxide and oxidative stress
7. Iron regulatory proteins in pathobiology
8. The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein-1 in cytosolic fractions of human myocardium
9. Cell-permeable superoxide dismutase and glutathione peroxidase mimetics afford superior protection against doxorubicin-induced cardiotoxicity: The role of reactive oxygen and nitrogen intermediates
10. Expression and biochemical characterization of iron regulatory proteins 1 and 2 in Saccharomyces cerevisiae
11. Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines
12. Inhibition by xipamide of amiloride-induced acidification in cultured rat cardiocytes
13. Cytoprotection by electromagnetic field-induced hsp70: A model for clinical application
14. Nuclear mitogen-activated protein kinase activation by protein kinase czeta during reoxygenation after ischemic hypoxia
15. A specific mRNA binding factor regulates the iron-dependent stability of cytoplasmic transferrin receptor mRNA
16. Transferrin receptor gene expression during rat liver regeneration. Evidence for post-transcriptional regulation by iron regulatory factorB, a second iron-responsive element-binding protein
17. High-performance liquid chromatographic determination of mitoxantrone in plasma utilizing non-bonded silica gel for solid-phase isolation to reduce adsorptive losses on glass during sample preparation
18. Bovine heart microsomes contain an Mr 66, 000 iron protein which stimulates NADPH oxidation
19. Phenoxyl free radical formation during the oxidation of the fluorescent dye 2′, 7′-dichlorofluorescein by horseradish peroxidase. Possible consequences for oxidative stress measurements
20. Murine cytotoxic activated macrophages inhibit aconitase in tumor cells. Inhibition involves the iron-sulfur prosthetic group and is reversible
21. Modification of a free Fe-S cluster cysteine residue in the active iron-responsive element-binding protein prevents RNA binding
22. Mutational analysis of the [4Fe-4S] cluster converting iron regulatory factor from its RNA-binding form to cytoplasmic aconitase
23. Free radical formation by antitumor quinones
24. Rat liver daunorubicin reductase. An aldo-keto reductase
25. Human carbonyl reductase overexpression in the heart advances the development of doxorubicininduced cardiotoxicity in transgenic mice
26. Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical
27. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer
28. Superoxide radical and iron modulate aconitase activity in mammalian cells
29. Human cytoplasmic aconitase (Iron regulatory protein 1) is converted into its [3Fe-4S] form by hydrogen peroxide in vitro but is not activated for iron-responsive element binding
30. Superoxide and hydrogen peroxide dependent inhibition of Iron Regulatory Protein activity: A protective stratagem against oxidative injury
31. Iron-dependent oxidation, ubiquitination, and degradation of iron regulatory protein 2: Implications for degradation of oxidized proteins
32. Thioredoxin activation of iron regulatory proteins. Redox regulation of RNA binding after exposure to nitric oxide
33. Control of transferrin receptor expression via nitric oxidemediated modulation of iron-regulatory protein 2
34. Concentrations of doxorubicin and its metabolites in human autopsy heart and other tissues
35. Anthracycline metabolism and toxicity in human myocardium: Role of cytoplasmic deglycosidation and carbonyl reduction
36. Inactivation of both RNA binding and aconitase activities of iron regulatory protein-1 by quinone-induced oxidative stress
37. Iron (II) is a modulator of ryanodine-sensitive calcium channels of cardiac muscle sarcoplasmic reticulum
38. B Disruption of mitochondrial calcium homeostasis following chronic doxorubicin administration
39. Myocyte cell damage after administration of doxorubicin or mitoxantrone in breast cancer patients assessed by indium III antimyosin monoclonal antibody studies
40. 1, 25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage
41. Antioxidant and xenobiotic-metabolizing enzyme gene expression in doxorubicinresistant MCF-7 breast cancer cells
42. Anthracyclines and their C-13 alcohol metabolites: Growth inhibition and DNA damage following incubation with tumor cell lines
43. Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells
44. Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction